Alector, Inc. develops clinical-stage biotechnology programs for neurodegenerative diseases, using genetics, immunology and neuroscience to pursue therapies that remove toxic proteins, replace missing proteins and restore immune and nerve cell function. News about ALEC commonly covers the Alector Brain Carrier (ABC) blood-brain barrier platform and ABC-enabled programs across antibodies, enzymes and siRNA.
Company updates focus on Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, frontotemporal dementia and other tauopathies, including candidates such as AL137, AL050 and AL064/AL164, as well as prior clinical programs including nivisnebart and latozinemab. Recurring announcements also include financial results, cash runway commentary, clinical trial results or discontinuations, research pipeline progress, investor conference participation and executive leadership changes.
Alector, Inc. (Nasdaq: ALEC) reported Q1 2024 financial results with $562.1 million in cash. The company is advancing its pipeline, strengthening leadership, and expects a data readout from the INVOKE-2 Phase 2 clinical trial of AL002 for early Alzheimer’s disease in Q4 2024. Alector also has a pivotal Phase 3 trial of latozinemab in FTD-GRN and a Phase 2 trial of AL101/GSK4527226 in early AD ongoing.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.